title: New directions in thrombolytic therapy.
abstract: Although current thrombolytic agents have proven their clinical benefit, the failure to rapidly reperfuse some patients and the persistent bleeding risk represent areas for improvement in therapy. In the past two years, the field has been advanced by the regulatory approval of agents with greater ease of administration, continued development of new agents and exploration of the use of more advanced antiplatelet therapies in combination with thrombolytic agents. Finally, a new class of directly acting fibrinolytic agents is available.
authors.affiliation: Product Development, Amgen Inc., Thousand Oaks, CA 91320, USA. ctoombs@amgen.com
authors.forename: C F
authors.initials: CF
authors.lastname: Toombs
mesh_terms: D000818:Animals; D001157:Arterial Occlusive Diseases / Q000188:drug therapy; D002405:Catheterization, Central Venous / Q000009:adverse effects / Q000379:methods; D000075202:Contraindications; D005337:Fibrin / Q000378:metabolism; D005343:Fibrinolytic Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D006083:Graft Occlusion, Vascular / Q000517:prevention & control; D006801:Humans; D008666:Metalloendopeptidases / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D010960:Plasminogen Activators / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D020521:Stroke / Q000188:drug therapy; D000077785:Tenecteplase; D015912:Thrombolytic Therapy / Q000009:adverse effects / Q000379:methods*; D010959:Tissue Plasminogen Activator / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D014568:Urokinase-Type Plasminogen Activator / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D005343:Fibrinolytic Agents; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011994:Recombinant Proteins; D005337:Fibrin; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator; D008666:Metalloendopeptidases; C436755:alfimeprase; C022653:auR protein, Staphylococcus aureus; C067551:saruplase; D000077785:Tenecteplase